on Relief Therapeutics Holdings AG (NASDAQ:RLFTF)
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
GENEVA (SEPT. 2, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY), a biopharmaceutical company focused on innovative treatments for rare diseases, announced that interim data from its clinical trial of PKU GOLIKE® will be presented at the SSIEM 2024 Annual Symposium in Porto, Portugal.
The study, conducted by the Inherited Metabolic Disorders Unit at Birmingham Children’s Hospital in the UK, compared PKU GOLIKE to standard amino acid substitutes in managing overnight phenylalanine (Phe) fluctuations in children with phenylketonuria (PKU).
Prof. Anita MacDonald will present preliminary results indicating that PKU GOLIKE reduces overnight blood phenylalanine levels and increases tyrosine levels more effectively than standard substitutes. Final results will be reported after ongoing data analysis.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holdings AG news